In the phase 3 CAHtalyst™ Pediatric trial (ClinicalTrials.gov Identifier: NCT04806451), researchers aimed to evaluate the efficacy and safety of CRENESSITY™ (crinecerfont) in lowering glucocorticoid ...

Hormones, diet, lifestyle, topical products, gut health, and stress all need to be assessed thoroughly with acne patients. In this case, the patient was able to resolve her acne by 90% at the last ...

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone ...

Those who had a reduction in androstenedione levels by week 4 were more likely to have a reduction in glucocorticoid dose by week 28 (crinecerfont, –18%; placebo, +6%; least squares mean ...

Crinecerfont Improves Reproductive Hormones in Classic Congenital Adrenal Hyperplasia: 1-Year Results from the Phase 3 CAHtalyst™ Adult Study (Presentation RC13.5) ...

Overproduction of androstenedione, a key adrenal androgen, in pediatric patients with congenital adrenal hyperplasia (CAH) can lead to abnormal growth and development, premature puberty and various ...

Androstenedione is a hormone produced by the adrenal glands, ovaries, and testes. It is commonly used as a dietary supplement to increase muscle mass, strength, and energy levels.

Estrogen is the Meryl Streep of hormones, its versatility renowned among scientists. Besides playing a key role in sexual and reproductive health, it strengthens bones, keeps skin supple ...

To document associations between anti-müllerian hormone (AMH) and circulating androgens in non-healthcare-seeking premenopausal women. Design Community-based, cross-sectional study. Setting Eastern ...

Androstenedione is one of those supplements that was peddled to athletes for years as a quick path to bulging muscles and high testosterone levels, but it comes with some serious side effects. Also ...

Spruce has trimmed the only drug from its pipeline in the wake of a second phase 2 trial this year, leaving the biotech’s future direction in doubt.